SEOUL-VIOSYS
2.9.2022 11:56:41 CEST | Business Wire | Press release
Seoul Viosys (“SVC”) (KOSDAQ: 092190), a manufacturer of optical semiconductor devices, will present micro-LED based on the laminated structure – which enables high-resolution display – as well as its micro-LED display products at the IFA (Internationale Funkausstellung Berlin) 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220902005087/en/
Remarkable color mixing technique developed based on Seoul Viosys’s unique technology (Graphic: Business Wire)
The stacked micro-LED developed by Seoul Viosys has a unique and innovative structure in which three chips representing red, green, and blue (R/G/B) are vertically arrayed instead of the usual horizontal array. Its main difference from conventional micro-LEDs is that its R/G/B LED in the stacked structure emit colors as if they constitute a single pixel through perfect color mixing.
Micro-LED produced by Seoul Viosys can achieve deep black color and clear image thanks to the stacked structure. Also, as colors combining R/G/B are emitted externally from inside a pixel, viewers can enjoy clear pictures without distortions from any direction.
The stacked micro-LED to be presented by Seoul Viosys at the exhibition is based on an innovative future technology that can manufacture 4K display screens between 100 and 200 inches. There will be a space where visitors can experience micro-LED in the company’s booth. It will show two micro-LED displays, including a 54-inch high-resolution 0.625mm pitch (P0.625) display and an 81.5-inch 0.9375mm pitch (P0.9375) display. Visitors will be able to enjoy highly immersive clear pictures wherein each pixel comes alive.
Various products representing key production processes of Seoul Viosys’s micro-LED, which have not been unveiled publicly, will also be on display. By exhibiting epitaxial wafers, cabinets, and other products fabricated using high-level transfer technology of moving micro-LED to a display substrate, the company will offer differentiated prices and quality while demonstrating its distinctive values.
In addition, Seoul Viosys will have an exhibition on its display LED techniques supporting its micro-LED technology, such as the molding technique that controls the moiré phenomenon and highlights the details of the black color, the low reflection technique that helps achieve vivid colors and high contrast ratios in the light, and the customized free form-factor design cabinet display that allows easy installation and replacement of microdisplay and change to various sizes.
As micro-LED has to run stably on extremely low power, it is difficult to achieve technological innovation without LED growth technology. Seoul Viosys already owns quantum efficiency enhancement technology for 1㎛-sized micro-LED through joint research with Nobel Laureate Shuji Nakamura, a professor at UC Santa Barbara, the U.S. The company also operates entire processes from the production of a red-green-blue light-emitting substrate to the manufacturing of devices and modules. Notably, WICOP, Seoul Viosys’s original technology, was applied to its micro-LED. WICOP is a key source technology that is necessary for producing micro-LED. It enables the fabrication of micro-scale chips by using no additional parts such as wires and has high reliability due to process simplification.
“By securing WICOP, a source technology for micro-LED and mini-LED, and quantum efficiency enhancement technology, Seoul Viosys is now ready to address any customer requests,” President Hwang Jeong-hwan of Seoul Viosys said. “Our micro-LED will enable the best image quality that viewers have never experienced before, and offer the top-notch solution in the rapidly changing large display market.”
He continued to say, “Seoul Viosys is introducing its products integrated for the purpose of providing a better solution to our customers, comprising LED, molding, and cabinet technologies, and demonstrating its competence,” once again stressing the company’s management principle of ‘no competition with customers.’
Seoul Viosys will introduce its Real One Pixel product that will be presented at the IFA 2022 on its social channels including YouTube (https://www.youtube.com/watch?v=kMJUzwxDqxk).
About Seoul Viosys
Seoul Viosys is a full-line solution provider for UV LED, VCSEL (Vertical Cavity Surface Emitting Laser), the next-generation light source for 3D sensor and laser, and a single-pixel RGB “Real One Pixel” for displays. Established in 2002 as a subsidiary of Seoul Semiconductor, it captured No. 1 market share in the UV LED industry (LEDinside, 2019). Seoul Viosys has an extensive UV LED portfolio with all wavelengths ranging from 200nm to 1600nm, including ultraviolet rays (UV), visible rays, and infrared rays. The company holds more than 4,000 patents related to UV LED technology. Violeds, its flagship UV LED technology, provides a wide range of industries with optimal solutions for robust sterilization and disinfection (UV-C), skin regeneration (UV-B), water/air purification and effective cultivation for horticulture. In 2018, Seoul Viosys acquired RayCan, a leading optoelectronic specialist, to add advanced VCSEL technology, which supports smartphone facial recognition and autonomous driving, and has started mass production. In January 2020, it introduced a disruptive “Real One Pixel” that has the potential to be a game-changer in the display market. To learn more, visit http://www.seoulviosys.com/en/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220902005087/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
